Free Trial

VanEck Bionic Engineering UCITS ETF A Acc (CYBG) Stock Chart & Stock Price History

GBX 13.48 +0.22 (+1.63%)
As of 06/5/2026 12:18 PM Eastern

VanEck Bionic Engineering UCITS ETF A Acc Stock Price Performance

The VanEck Bionic Engineering UCITS ETF A Acc (CYBG) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 11.51%, with a year-to-date return of -14.00%. In the past month, the stock has increased 2.78%, reflecting recent market activity.

As of the latest close, VanEck Bionic Engineering UCITS ETF A Acc traded at GBX 13.48 with a market cap of £193.31 million and volume of 197 shares. Five years ago, the stock traded at GBX 137.60, representing a 90.21% decrease over that period. At the time, it had a market cap of £2.08 billion and a volume of 2.42 million shares.

Receive CYBG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VanEck Bionic Engineering UCITS ETF A Acc and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
5 Day
Performance
+4.77%
1 Month
Performance
+2.78%
3 Month
Performance
-10.35%
Year-To-Date
Performance
-14.00%
1 Year
Performance
N/A
5 Year
Performance
-90.21%

CYBG Stock Chart for Sunday, June, 7, 2026

VanEck Bionic Engineering UCITS ETF A Acc Stock Price History

DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization
06/05/2026GBX 13.30GBX 13.48
+1.35%
GBX 13.48GBX 13.21197 shs£193.31 million
06/04/2026GBX 12.80GBX 13.30
+3.87%
GBX 13.39GBX 13.0394 shs£190.73 million
06/03/2026GBX 12.86GBX 12.80
-0.48%
GBX 12.93GBX 12.80618 shs£183.62 million
06/02/2026GBX 13.01GBX 12.86
-1.12%
GBX 13.04GBX 12.83100 shs£184.50 million
06/01/2026GBX 13.17GBX 13.01
-1.20%
GBX 13.18GBX 12.91950 shs£186.60 million
05/29/2026GBX 13.12GBX 13.17
+0.34%
GBX 13.18GBX 13.10640 shs£188.87 million
05/28/2026GBX 13.33GBX 13.12
-1.52%
GBX 13.13GBX 13.09190 shs£188.23 million
05/27/2026GBX 13.33GBX 13.33GBX 13.43GBX 13.33149 shs£191.15 million
05/26/2026GBX 13.37GBX 13.33
-0.34%
GBX 13.43GBX 13.33149 shs£191.15 million
05/25/2026GBX 13.37GBX 13.37GBX 13.38GBX 13.3088 shs£191.79 million
05/22/2026GBX 13.38GBX 13.38GBX 13.38GBX 13.3088 shs£191.89 million
05/21/2026GBX 13.34GBX 13.38
+0.31%
GBX 13.38GBX 13.3088 shs£191.89 million
05/20/2026GBX 12.93GBX 13.34
+3.18%
GBX 13.34GBX 13.341 shs£191.30 million
05/19/2026GBX 12.93GBX 12.93GBX 12.93GBX 12.93386 shs£185.41 million
05/18/2026GBX 12.94GBX 12.93
-0.13%
GBX 12.93GBX 12.93386 shs£185.41 million
05/15/2026GBX 12.77GBX 12.77GBX 12.78GBX 12.77141 shs£183.11 million
05/14/2026GBX 12.70GBX 12.77
+0.48%
GBX 12.78GBX 12.77141 shs£183.11 million
05/13/2026GBX 12.43GBX 12.70
+2.21%
GBX 12.75GBX 12.70273 shs£182.24 million
05/12/2026GBX 12.75GBX 12.43
-2.54%
GBX 12.43GBX 12.4338 shs£178.29 million
05/11/2026GBX 12.78GBX 12.75
-0.20%
GBX 12.75GBX 12.6846 shs£182.94 million
05/08/2026GBX 13.11GBX 12.78
-2.54%
GBX 13.07GBX 12.78792 shs£183.30 million
05/07/2026GBX 13.25GBX 13.11
-1.08%
GBX 13.11GBX 13.05290 shs£188.08 million
05/06/2026GBX 13.24GBX 13.25
+0.14%
GBX 13.29GBX 13.12859 shs£190.13 million

This page (LON:CYBG) was last updated on 6/7/2026 by MarketBeat.com Staff.
From Our Partners